nebival 5 mg/1 tableta tableta
novartis ba d.o.o. - Небиволол - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg nebivolol (u obliku nebivololhidrohlorida)
nibel 5 mg/1 tableta tableta
farmavita d.o.o. sarajevo - Небиволол - tableta - 5 mg/1 tableta - 1 tableta sadrži: 5 mg nebivolol (u obliku nebivololhidrohlorida)
lucentis 10 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba
lucentis 10 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - ranibizumab - rastvor za injekciju - 10 mg/1 ml - 1 ml rastvora za injekciju sadrži: 10 mg (2,3 mg/0,23 ml) ranibizumaba
oxervate
dompe farmaceutici s.p.a. - recombinant human nerve growth factor - keratitis - ophthalmologicals - liječenje umjereno (uporni epitelnih kvar) ili teške (čir) neurotrophic keratitisa u odraslih.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
beovu 120 mg/1 ml rastvor za injekciju
novartis ba d.o.o. - brolucizumab - rastvor za injekciju - 120 mg/1 ml - 1staklena bočica sadrži: 27,6 mg brolucizimaba u 0,23 ml rastvora
beovu 120 mg/1 ml rastvor za injekciju u napunjenom špricu
novartis ba d.o.o. - brolucizumab - rastvor za injekciju u napunjenom špricu - 120 mg/1 ml - jedna napunjena šprica sadrži 19,8 mg brolucizumaba u 0,165 ml rastvora